AZN - AstraZeneca PLC

NYSE - NYSE Delayed Price. Currency in USD
39.59
+0.10 (+0.25%)
At close: 4:03PM EDT

39.59 0.00 (0.00%)
After hours: 4:51PM EDT

Stock chart is not supported by your current browser
Previous Close39.49
Open39.16
Bid39.30 x 4000
Ask39.70 x 2200
Day's Range39.03 - 39.76
52 Week Range31.99 - 40.16
Volume4,603,426
Avg. Volume4,124,900
Market Cap99.673B
Beta (3Y Monthly)0.53
PE Ratio (TTM)37.53
EPS (TTM)1.05
Earnings DateN/A
Forward Dividend & Yield1.40 (3.59%)
Ex-Dividend Date2018-08-09
1y Target Est41.66
Trade prices are not sourced from all markets
  • AstraZeneca dips, Harley-Davidson plummets, Johnson & Johnson down slightly
    Yahoo Finance5 hours ago

    AstraZeneca dips, Harley-Davidson plummets, Johnson & Johnson down slightly

    AstraZeneca, Harley-Davidson and Johnson and Johnson are the Yahoo Finance charts of the day.

  • The Wall Street Journal8 hours ago

    [$$] AstraZeneca Adds Cancer Drugs to Pipeline

    PLC has struck a deal with a French biotechnology firm to add a promising cancer drug to its pipeline, boosting its focus on oncology as part of broader strategy to double sales in the next five years. AstraZeneca will also gain access to a second cancer drug in Innate’s pipeline, dubbed IPH5201, and the right to license four to-be-agreed medicines in early-stage development at the French company. AstraZeneca will also take a 9.8% stake in Innate Pharma.

  • How Novartis’s Alcon Performed in Third Quarter
    Market Realist9 hours ago

    How Novartis’s Alcon Performed in Third Quarter

    Alcon, the eye care business of Novartis AG (NVS), includes surgical products and vision care products. Alcon reported revenues of ~$1.76 billion during the third quarter of 2018, a 3% increase in year-over-year (or YoY) revenues as compared to ~$1.71 billion in the third quarter of 2017. The growth was driven by a 5% growth in operating revenues, offset by a 2% negative impact of foreign exchange.

  • Reuters14 hours ago

    AstraZeneca digs deeper into cancer with Innate stake

    LONDON/PARIS (Reuters) - AstraZeneca is ploughing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.8 percent stake in the French biotech company. Tuesday's agreement is a coup for Innate - run by former AstraZeneca executive Mondher Mahjoubi - which gains rights to sell AstraZeneca's newly approved rare blood cancer drug Lumoxiti as its first commercial product. AstraZeneca's purchase of 6.26 million new shares in Innate at a price of 10 euros each, or double the market rate, marks a vote of confidence in the cancer immunotherapy specialist and Innate shares jumped 29 percent on the deal news.

  • Reuters14 hours ago

    AstraZeneca digs deeper into cancer with Innate stake

    LONDON/PARIS, Oct 23 (Reuters) - AstraZeneca is ploughing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.8 percent stake in the French biotech company. Tuesday's agreement is a coup for Innate - run by former AstraZeneca executive Mondher Mahjoubi - which gains rights to sell AstraZeneca's newly approved rare blood cancer drug Lumoxiti as its first commercial product.

  • Why Tesaro, Inc. Is Tanking Today
    Motley Foolyesterday

    Why Tesaro, Inc. Is Tanking Today

    Good news for a rival drug translates to bad news for Tesaro.

  • How Novartis’s Business Segments Performed in the Third Quarter
    Market Realistyesterday

    How Novartis’s Business Segments Performed in the Third Quarter

    As discussed earlier, Novartis (NVS) missed Wall Street analysts’ estimates for revenues with reported revenues of ~$12.78 billion during the third quarter of 2018, a 2.9% increase in YoY revenues. Novartis AG is the holding company providing healthcare solutions, and its business is classified into three business segments including the Innovative Medicines segment, Sandoz, and Alcon. The below chart shows the revenue performance of Novartis’s segments since the first quarter of 2017. 

  • Here's Why Clovis Oncology Dropped as Much as 21.2% Today
    Motley Foolyesterday

    Here's Why Clovis Oncology Dropped as Much as 21.2% Today

    The biopharma stock fell on excellent news -- for the competition.

  • Business Wireyesterday

    AstraZeneca to Present New Data Demonstrating Breadth of Research Portfolio in Renal Disease at ASN Kidney Week 2018

    35 scientific data presentations and publications, including new evidence for LOKELMA™ in hyperkalemia and FARXIGA® on renal endpoi

  • Solo-1 Phase III Trial Demonstrates Lynparza Maintenance Therapy Cut the Risk of Disease Progression or Death by 70% in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer
    Business Wire2 days ago

    Solo-1 Phase III Trial Demonstrates Lynparza Maintenance Therapy Cut the Risk of Disease Progression or Death by 70% in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer

    60% of patients receiving LYNPARZA remained progression-free at three years compared to 27% on placebo following platinum-based chemotherapy

  • AstraZeneca, Harley-Davidson and Johnson and Johnson are the Yahoo Finance charts of the day.
    Yahoo Finance Video7 hours ago

    AstraZeneca, Harley-Davidson and Johnson and Johnson are the Yahoo Finance charts of the day.

    Let's check out the Yahoo Finance charts of the day. AstraZeneca (AZN ): Shares are down in early trade,  at around .61%. The drugmaker has  a wide-ranging deal with French biotech company Innate Pharma, which includes the British group buying a 9.8 percent stake in the biotech company.    Harley-Davidson (HOG ): Shares down here, 4.0%. The motorcycle company beat estimates by 15 cents a share, with a 68 cent per share profit. They beat on the top line with improved European sales and a full-year motorcycle shipment forecast.  Johnson and Johnson  (JNJ): Shares down here, around .74%.  The healthcare company  is offering 2.1 billion for the portion of Japanese cosmetic firm, Ci:z Holdings, that it doesn't already own.  J&J had held 19.9 percent of the outstanding shares. For more on today's big stock movers check out the Final Round, live at 3:30 p.m. ET, right here on Yahoo Finance